Barion Pixel

Hírek

FDA approves Roche’s Wilserdly for ESR1-mutated advanced breast cancer

On Monday the FDA approved Roche’s breast cancer drug Wilserdly (giredestrant), an oral selective estrogen receptor degrader, for HR-positive, HER2-negative advanced disease with an ESR1 mutation. In the evERA trial it delayed tumor progression, and Roche has said it could become its best-selling me